FRESCO-2: A global/multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer

T. Yoshino,N. A. Dasari, S. Lonardi,R. Garcia-Carbonero,M. E. Elez Fernandez,A. Sobrero, J. C. Yao,P. Garcia Alfonso,J. Kocsis,A. Cubillo Gracian,A. Sartore Bianchi,V. Randrian, J. Tomasek, G. Chong,Z. Yang, W. Schelman, M. Kania,J. Tabernero, C. Eng,T. Satoh

Annals of Oncology（2022）

引用 0|浏览2

暂无评分

摘要

Effective treatment options are limited for patients (pts) with refractory metastatic colorectal cancer (mCRC). Fruquintinib (F), a highly selective, potent, oral tyrosine kinase inhibitor of VEGFR-1, -2, and -3 was approved in China in the 3L+ mCRC setting based on results from the FRESCO trial (NCT02314819). FRESCO-2 (NCT04322539) evaluated F in more heavily pretreated pts reflecting current global practices.

查看译文

关键词

metastatic colorectal cancer,colorectal cancer,fruquintinib,clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要